Semaglutide is an FDA-approved GLP-1 medication that is self-injected under the skin using a tiny insulin needle once a week (every seven days), day or night, with or without food
Negative measurement bias ranged from -0.01 to -0.31 for 59% of the sample and was predominantly explained by social needs, demographics, and medications (d = 33%, 18%, 16%, respectively
Researchers should resist the temptation to escalate faster than the standard protocol, as doing so increases the likelihood and severity of GI events
Mao R, Kurada S, Gordon IO, Baker ME, Gandhi N, McDonald C, et al
These initial results also help identify pre-existing conditions that may affect treatment decisions or require additional monitoring
A HEALTHY BODY IS A RESPONSIVE BODY